
- Telehealth Visits

Martin Thelin, MD
Pediatric EndocrinologyDirector, Pediatric Lipid Clinic


Martin Thelin, MD
Pediatric EndocrinologyDirector, Pediatric Lipid Clinic- Telehealth Visits
On this page
About me
Dr. Martin Thelin is a pediatric endocrinologist who cares for children and adolescents with cholesterol and triglyceride disorders. He leads the Pediatric Lipid Clinic at UCSF, providing comprehensive evaluation and management of lipid disorders (abnormal fat and cholesterol levels in the blood) in young patients. His goal is to prevent early-onset cardiovascular disease by diagnosing lipid abnormalities early and tailoring therapies — including lifestyle coaching, family-centered education and new medications — to each child's needs.
In research, Thelin is interested in how inflammation, autoimmunity and metabolic dysfunction in childhood are linked to faulty lipid metabolism (the formation and breakdown of lipids), with a particular focus on the connection between lipid disorders and immune dysregulation. Working closely with families, clinical teams and laboratory scientists, he aims to advance innovative therapies for children with high-risk or genetic lipid abnormalities.
Thelin earned his medical degree and doctorate in biochemistry from Lund University in Sweden. He completed a residency in pediatrics and a fellowship in pediatric endocrinology at UCSF. He also completed postdoctoral training in immunology and type 1 diabetes at the Joslin Diabetes Center, an affiliate of Harvard Medical School.
Education
Board Certification
- Pediatrics, American Board of Pediatrics
- Endocrinology and Metabolism, American Board of Pediatrics
Fellowship
- Pediatric Endocrinology, UCSF School of Medicine -GME
Residency
- Pediatrics, UCSF School of Medicine -GME
School
- MD, Lund University
Academic Title
- Adjunct Professor
Care Keywords
Services
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaOpens in a new window
Recruiting
Demonstrate superiority of inclisiran compared to placebo in reducing LDL-C [percent change] at Day 330Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaOpens in a new window
Recruiting
Evaluate the effect of inclisiran compared to placebo on reducing LDL-C [percent change] at Day 330
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
